The Lowy Medical Research Institute Limited Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01327911
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Lowy Medical Research Institute | The Lowy Medical Research Institute Limited

Active Ingredients

Drugs in Phase 2 Trials (4)

ciliary neurotrophic factor (1 trial)

fenofibrate (fenoglide) (1 trial)

l-serine (1 trial)

nt-501 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Telangiectasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4